Dr. Carol Aghajanian, Chief of Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center, discusses several new therapies she and her colleagues are developing to enhance the effectiveness of chemotherapy for ovarian cancer. These novel approaches target a variety of biological and genetic factors that contribute to the disease.

Learn about MSK: [ Ссылка ]

CONNECT WITH MSK
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
Instagram: [ Ссылка ]

Request an appointment at MSK by calling 800-525-2225 or online at: [ Ссылка ]


{partial transcript}

Good afternoon everybody. I see a lot of familiar faces in the audience and I want to thank you all for coming.

I’m going to start with a brief introduction to set the scene for the scientist and investigators that we’ve invited to speak with you today. This is our opportunity during gynecologic cancer awareness month to give you guys a sneak peak at all that’s going on behind the scenes in terms of our research programs looking to improve the therapy for women with ovarian cancer.

As you all know, with ovarian cancer we are talking about people with stage three or four disease. The disease is usually diagnosed in stages three or four. That said, we deal with these stages in most of our trials.

Screening methods have so far proven to be difficult and efforts are ongoing. The next slide will explain how that might be. Ovarian cancer is a cancer that instead of being a lump in the breast…

свернуть